Tags : Rubraca

Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3

Shots: The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib, 600mg, bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with an epithelial ovarian, fallopian tube or primary peritoneal cancer The P-III ARIEL3 study results: IIT population & BRCA mutation, Mean QA-PFS in (12.02 vs 5.74 […]Read More